BerGenBio Partners with Tempus on Cancer Treatment

BerGenBio ASA (BRRGF) has released an update.

BerGenBio ASA has announced a collaboration with AI technology company Tempus to enhance the clinical development of its AXL inhibitor, bemcentinib, for treating Non-Small Cell Lung Cancer with STK11 mutations. The partnership will leverage real-world data and AI analytics from Tempus to establish a synthetic control group, aiming to improve treatment outcomes and set a new standard of care for this patient group. Excited leaders from both companies anticipate that the insights from this study will expedite the advancement of bemcentinib.

For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.